Gynecologic Cancer
News
Race, ethnicity influence chances of minimally invasive hysterectomy
Major finding: Black women were 43% less likely to have a minimally invasive hysterectomy for endometrial cancer than were white women.
News
In phase III trial, bevacizumab prolongs progression-free survival for ovarian cancer
Major findings: The hazard ratios for overall survival were 0.78 (P = .007) in "high-risk" newly diagnosed patients and 0.85 (P = .174) in...
News
Single dose of HPV16/18 vaccine appears immunogenic
Major finding: All women who received at least one dose of the HPV16/18 VLP vaccine showed protective levels of antibodies 4 years later; among...
News
Hormone therapy’s protection against endometrial cancer persists in Women’s Health Initiative follow-up study
Major finding: HT was associated with a 35% reduction in the risk for endometrial cancer (P = .007) when compared with placebo.Data source: The...
News
Many women with cancer not told about impaired fertility risk
Major finding: Less than half of all women of reproductive age with a diagnosis of cancer were told by physicians that treatment might affect...
News
Cisplatin and radiation improve DFS in stage IIIB cervical cancer
Major finding: The hazard ratio for disease-free survival with the addition of cisplatin was 0.52 compared with external beam radiation and...
News
ICON6 ovarian cancer results may resurrect cediranib
Major finding: Median progression-free survival was 8.7 months platinum-based chemotherapy plus placebo maintenance and 11.1 months with cediranib...
News
TRINOVA-1 signals new direction in ovarian cancer
Major finding: Progression-free survival was 7.2 months with paclitaxel plus trebananib vs.
News
BMN 673 monotherapy makes splash in BRCA-mutated ovarian, breast cancer
Major finding: The RECIST response rate was 44% for breast and ovarian cancer patients.Data source: Ongoing phase I/II study in ovarian and breast...
News
Biweekly 5-fluorouracil cream beat back cervical neoplasia
Major finding: CIN 2 regressed in 96% of women treated with 2 g of intravaginal 5-fluorouracil every 2 weeks for 16 weeks; disease regressed in 57...
News
Weekly chemo offers quality-of-life edge in advanced ovarian cancer
Major Finding: Compared with the standard every-3-week regimen, the weekly regimen did not yield significantly better progression-free or overall...